Lung cancer Posts on Medivizor
Navigation Menu

Lung cancer Posts on Medivizor

Evaluating the long-term outcomes of stereotactic ablative radiation therapy and video-assisted thoracic surgery in patients with early-stage non-small cell lung cancer.

Evaluating the long-term outcomes of stereotactic ablative radiation therapy and video-assisted thoracic surgery in patients with early-stage non-small cell lung cancer.

Posted by on Oct 24, 2021 in Lung cancer | 0 comments

In a nutshell This study evaluated the long-term outcomes of stereotactic ablative radiation therapy (SABR) and video-assisted thoracic surgery (VATS) for the treatment of patients with early-stage non-small cell lung cancer (NSCLC). The data showed that both SABR and VATS led to similar long-term survival outcomes. Some background...

Read More

Evaluating the safety and effectiveness of trastuzumab deruxtecan in HER2-mutant non–small-cell lung cancer.

Evaluating the safety and effectiveness of trastuzumab deruxtecan in HER2-mutant non–small-cell lung cancer.

Posted by on Oct 24, 2021 in Lung cancer | 0 comments

In a nutshell This study evaluated the effectiveness and safety of trastuzumab deruxtecan (Enhertu) in patients with previously untreated metastatic HER2-mutant non-small-cell lung cancer (NSCLC). The data showed that trastuzumab deruxtecan was safe and showed strong anticancer activity in these patients. Some background NSCLC is the most common form...

Read More

Comparing the effectiveness and safety of nivolumab plus ipilimumab with chemotherapy versus pembrolizumab plus chemotherapy as first-Line treatment for metastatic NSCLC.

Comparing the effectiveness and safety of nivolumab plus ipilimumab with chemotherapy versus pembrolizumab plus chemotherapy as first-Line treatment for metastatic NSCLC.

Posted by on Oct 17, 2021 in Lung cancer | 0 comments

In a nutshell This study compared the effectiveness and safety outcomes of nivolumab (N; Opdivo) plus ipilimumab (I; Yervoy) with chemotherapy versus pembrolizumab (Pem; Keytruda) plus chemotherapy as first-line treatment in patients with metastatic non-small cell lung cancer (NSCLC). The data showed that N-I plus chemotherapy provided similar overall...

Read More

Comparing the effectiveness and safety of single and double immune checkpoint inhibitor-based first-line treatments for advanced non-small cell lung cancer.

Comparing the effectiveness and safety of single and double immune checkpoint inhibitor-based first-line treatments for advanced non-small cell lung cancer.

Posted by on Oct 16, 2021 in Lung cancer | 0 comments

In a nutshell This study compared the effectiveness and safety outcomes of single and double immune checkpoint inhibitors (ICI)-based treatments in patients with advanced non-small-cell lung cancer (NSCLC). The data showed that the effectiveness and safety of both single and double ICI-based treatments were similar and higher...

Read More

Evaluating the benefits of radiotherapy after surgery in patients with resectable stage III-N2 non-small cell lung cancer.

Evaluating the benefits of radiotherapy after surgery in patients with resectable stage III-N2 non-small cell lung cancer.

Posted by on Oct 16, 2021 in Lung cancer | 0 comments

In a nutshell This study evaluated the benefits of postoperative radiotherapy (PORT; radiation after surgery) in patients with resectable stage III-N2 non-small-cell lung cancer (NSCLC). The data showed that PORT significantly increased survival without disease progression and reduced the risk of cancer relapse for these patients. Some background...

Read More

Is cancer treatment with immune checkpoint inhibitors associated with infection risk?

Is cancer treatment with immune checkpoint inhibitors associated with infection risk?

Posted by on Oct 9, 2021 in Lung cancer | 0 comments

In a nutshell This study is aimed to evaluate the risk of infection for patients who are treated with immune checkpoint inhibitors (ICI) for solid tumors. The study concluded that in frail patients, ICI therapy alone is safer compared to chemotherapy (CT).   Some background Immunotherapy is a type of cancer treatment that makes use of the immune...

Read More

Does tyrosine kinase inhibitors therapy after surgery benefit patients with EGFR-mutant resected NSCLC?

Does tyrosine kinase inhibitors therapy after surgery benefit patients with EGFR-mutant resected NSCLC?

Posted by on Oct 9, 2021 in Lung cancer | 0 comments

In a nutshell This study evaluated whether patients with non-small-cell lung cancer (NSCLC) having genetic mutations could benefit from epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) therapy after surgery. The data showed that EGFR-TKI therapy after surgery significantly improved survival without disease progression in...

Read More

Is osimertinib an effective treatment for EGFR-mutant advanced non-small cell lung cancer in a real-world practice?

Is osimertinib an effective treatment for EGFR-mutant advanced non-small cell lung cancer in a real-world practice?

Posted by on Oct 3, 2021 in Lung cancer | 0 comments

In a nutshell This study looked at the use of osimertinib (Tagrisso) for the treatment of EGFR-mutant advanced non-small-cell lung cancer (NSCLC) in a real-world practice. It found that osimertinib was confirmed to improve survival without cancer progressing, while the occurrence of blood clots was more common in a real-world...

Read More

Evaluating the effectiveness and safety of anlotinib combined with radiotherapy to the head for patients with brain metastases from NSCLC.

Evaluating the effectiveness and safety of anlotinib combined with radiotherapy to the head for patients with brain metastases from NSCLC.

Posted by on Oct 3, 2021 in Lung cancer | 0 comments

In a nutshell This study evaluated the effectiveness and safety of combining cranial radiotherapy (CRT; radiotherapy tot the head) with and without anlotinib (AL3818) for the treatment of patients with non-small cell lung cancer (NSCLC) and brain metastases (BM). The data showed that anlotinib plus CRT significantly improved survival without brain...

Read More

Evaluating the effect of brain metastases status on immunotherapy effectiveness in advanced lung cancer.

Evaluating the effect of brain metastases status on immunotherapy effectiveness in advanced lung cancer.

Posted by on Sep 28, 2021 in Lung cancer | 0 comments

In a nutshell This study evaluated the effect of brain metastases (BMs) status on immunotherapy effectiveness in patients with advanced lung cancer (LC). The data showed that the effectiveness of immunotherapy was similar in patients with or without BMs. Some background In 20-40% of patients with advanced LC, cancer spreads from the lung to the brain...

Read More

Do tyrosine kinase inhibitors benefit patients with mutant inoperable NSCLC?

Do tyrosine kinase inhibitors benefit patients with mutant inoperable NSCLC?

Posted by on Sep 16, 2021 in Lung cancer | 0 comments

In a nutshell This study evaluated whether patients with unresectable non-small-cell lung cancer (NSCLC) having genetic mutations could benefit from first-line treatment with tyrosine kinase inhibitor (TKI) therapy. The data showed that TKIs could be a good option for these patients. Some background NSCLC is the most common form of lung cancer....

Read More

Evaluating the best timing of surgery after chemoradiotherapy in patients with locally advanced non-small cell lung cancer.

Evaluating the best timing of surgery after chemoradiotherapy in patients with locally advanced non-small cell lung cancer.

Posted by on Sep 12, 2021 in Lung cancer | 0 comments

In a nutshell This study investigated the optimal time interval between chemoradiotherapy (CRT) and surgery and its impact on survival outcomes in patients with locally advanced (LA) non-small-cell lung cancer (NSCLC). The data showed that surgery within 7 weeks after CRT was associated with improved survival outcomes in these patients. Some...

Read More